Trial · NCT07893197
Ceritinib Treatment for Recurrent Meningiomas
NCT07893197, Phase 2, Not yet recruiting, Kevin Petrecca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ceritinib Treatment for Recurrent Meningiomas. Trials, record NCT07893197. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893197
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ceritinib Treatment for Recurrent Meningiomas
- NCT number
- NCT07893197
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Kevin Petrecca
- Conditions
- Recurrent Meningioma, Grade I and Grade II
- Interventions
- Ceritinib
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | From enrolment to safety follow up at week 90 | Response Evaluation Criteria in Solid Tumors (RECIST 1.1) applied to MRIs (Axial, pre- and post- gadolinium-enhanced 3D T1-weighted IR-GRE with \<1mm resolution) at each study visit |
| Primary | Investigator-assessed Overall Response Rate (ORR) | From enrolment to safety follow up at week 90 | Response Evaluation Criteria in Solid Tumors (RECIST 1.1) applied to magnetic resonant imaging (MRIs) (Axial, pre- and post- gadolinium-enhanced 3D T1-weighted IR-GRE with \<1mm resolution) at each study visit |
| Primary | Overall Survival of patients with recurrent grade 1 or 2 meningioma | From enrolment to safety follow up at week 90 | Overall survival is defined as the period from the baseline visit (V1) until death. |
| Secondary | Incidence of Severe Adverse Events related to the study drug | From enrolment to safety follow up at week 90 | Grade of Adverse Events classified as per CTCAE v6.0. The higher the grade, the worse and more severe the event. |
| Secondary | Incidence of Adverse Events related to the study drug | From enrolment to safety follow up at week 90 | Grade of Adverse Events classified as per CTCAE v6.0. The higher the grade, the worse and more severe the event. |
| Secondary | Liver toxicology panel measured in blood (AST, ALT, ALP, total bilirubin) | From enrolment to safety follow up at week 90 | Liver toxicity indicators in blood: Aspertate aminotransferase (AST) (U/L, Reference range: 6-35), Alanine aminotransferase (ALT) (U/L, Reference range: 6-45), total bilirubin (umol/L, 1.7-18.9), alkaline phosphatase (ALP) |
| Secondary | Calcium in blood serum | From enrolment to safety follow up at week 90 | Reference range for calcium concentration in serum: 2.12-2.62 mml/L |
| Secondary | Total White Blood Cell Count in Blood | From enrolment to safety follow up at week 90 | White Blood Cell Count (Reference Range: 4.5-11 10\^9/L). Can be further subdevided into different types of white blood cells including: Neutrophils (1.88-7.7 10\^9/L), Lymphocytes (1-4.8 10\^9/L), Monocytes (0-0.8 10\^9/L), Eosinophils (0-0.45 10\^9/L), Basophils (0-0.022 10\^9/L). |
| Secondary | Serum Lipase | From enrolment to safety follow up at week 90 | Determined in serum. Reference range: 14-45 umol/L |
| Secondary | Urinalysis-Dipstick | From enrolment to safety follow up at week 90 | Dipstick measures several values at once: pH (measured in logarithmic units from 0-14, 7 is normal), amount of protein (Normal reference range: under 10-14 mg/dL), glucose (Normal reference range: 0 to 15 mg/dL or 0 to 0.8 mmol/L), ketones (measured in mmol/L), blood (normal: 3 to 4 red blood cells per high power field), nitrites (measured as positive or negative, no scale), leukocyte esterase (measured in leukocytes per microliter) |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893197
GET https://conductscience.org/api/trials/v1/NCT07893197/registered?page=2